This site contains information about prescription peptide therapy protocols intended for adults. You must be 18 years of age or older to enter.
By entering, you confirm you are at least 18 years old and agree to our Terms of Service. All protocols require a valid physician prescription.
Cyclic heptapeptide studied for UV-independent skin pigmentation, sexual function via MC4R activation, and appetite regulation. Broader receptor activity than PT-141 — with meaningful results and a steeper tolerance curve.
Melanotan II is a synthetic cyclic analogue of alpha-melanocyte stimulating hormone (α-MSH) — a naturally occurring peptide in the melanocortin system. Where PT-141 (bremelanotide) was engineered for receptor selectivity toward MC3R and MC4R, MT-II is nonselective: it activates MC1R, MC3R, and MC4R simultaneously, producing a broader physiological response across tanning, sexual function, and appetite regulation.
It emerged from University of Arizona research in the late 1980s as scientists searched for a way to induce skin pigmentation without UV exposure. The intent was skin cancer prevention — increasing melanin production through a different route. That research eventually produced both MT-II and its more selective descendant, PT-141. MT-II never reached FDA approval; PT-141 did (as Vyleesi, 2019).
The melanogenesis effect is real and well-documented in early Phase I work: subjects developed measurable, lasting tanning activity after a short loading series without UV exposure. This, combined with the MC4R-mediated sexual function effects, is why it has remained in continuous underground demand for over three decades — and why supply consistently can't keep up with interest.
MT-II's activity is best understood receptor by receptor. Unlike more targeted peptides, it activates all three simultaneously — which explains both its utility and its side effect profile.
Expressed in melanocytes — the pigment-producing cells of the skin. MC1R activation triggers melanogenesis: the production of eumelanin (brown/black pigment). The result is a tan that develops over days to weeks and persists longer than UV-induced pigmentation. The effect is dose-dependent and cumulative with loading.
Expressed in the brain, gut, and heart. MC3R plays a role in energy homeostasis and anti-inflammatory signaling. Activation contributes to appetite modulation and may account for some of the mood-adjacent effects reported anecdotally. Less well-studied than MC1R/MC4R in human models.
Expressed in the hypothalamus. MC4R activation drives two of MT-II's most reported effects: sexual arousal (via dopamine pathway modulation, producing erection in males and sexual desire in females) and appetite suppression. PT-141's mechanism is almost entirely here — MT-II hits this receptor plus the two above.
Stimulates eumelanin production through MC1R without requiring UV radiation. Tan develops over days to weeks of loading and persists significantly longer than sun exposure alone.
MC4R-mediated activation of the dopamine reward pathway increases sexual desire and facilitates arousal in both males and females. Mechanism is central, not vascular — works through desire, not blood flow.
MC4R activation in the hypothalamus produces appetite suppression in many users. Some researchers note this as a secondary benefit during loading; effect diminishes at maintenance doses for others.
Original intent of the Arizona research program: higher melanin levels offer baseline UV protection. Research has explored whether peptide-induced melanogenesis confers protective benefit in photosensitive skin models.
MC3R and MC4R interaction with dopaminergic pathways has been associated with anecdotal reports of elevated mood and motivation during active dosing. Not a primary research focus but frequently noted.
MT-II's nonselective receptor profile makes it a useful tool for studying the full melanocortin axis in research models — characterizing all three receptor subtypes simultaneously versus selective agonists.
PT-141 (bremelanotide) was derived directly from MT-II research — it was engineered to isolate the sexual function effect by increasing selectivity for MC3R and MC4R and removing the MC1R tanning activity. Understanding the difference clarifies when each is the better research subject.
| Parameter | Melanotan II (MT-II) | PT-141 (Bremelanotide) |
|---|---|---|
| Receptor Profile | MC1R, MC3R, MC4R (nonselective) | MC3R, MC4R (selective) |
| Tanning Effect | Yes — MC1R drives melanogenesis | None |
| Sexual Function | Yes — MC4R mediated | Yes — primary mechanism |
| Nausea Risk | Higher, especially early in loading | Lower (dose-dependent) |
| FDA Status | Not approved | Approved as Vyleesi (2019) |
| Typical Dose | 0.25–1.0mg SC | 1.75mg SC standard |
| Spontaneous Erection | More common — especially at higher doses | Less common |
| Duration of Effect | 4–6 hours (acute); tanning persists weeks | 6–8 hours |
| Timing (for sexual use) | 45–90 min before | 45–90 min before |
Note: Do not combine MT-II and PT-141. Both target overlapping melanocortin receptors — combining them multiplies side effect risk without proportional benefit.
MT-II carries a steeper tolerance curve than most peptides in this catalog. Start significantly lower than the target dose — nausea is dose-dependent and front-loaded in the loading phase. Titrating up over the first week dramatically reduces side effect burden.
| Phase | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Sensitivity Test | 0.1–0.25mg SC | Once | Day 1 | Assess tolerance before committing to a loading protocol. Administer at bedtime — nausea, if it occurs, passes during sleep. |
| Loading (Tanning) | 0.5mg SC | Daily or every other day | 2–4 weeks | Tanning develops gradually over the loading period. Low-level UV exposure (5–10 min/day) amplifies the pigmentation response but is not required. |
| Maintenance | 0.25–0.5mg SC | 1–2x per week | As desired | Maintains pigmentation. Many researchers find once-weekly dosing sufficient after a full loading phase. |
| Sexual Function (acute) | 0.5–1.0mg SC | As needed | Single dose | Administer 45–90 minutes before. Keep to the lower end of the range — 1mg significantly increases nausea risk. Fasted or light meal preferred. |
Early University of Arizona Phase I work demonstrated measurable skin pigmentation in human subjects following a short loading series — without UV exposure. Effect was sustained beyond the active dosing period.
MT-II's tanning effect operates through MC1R in melanocytes — the same pathway UV radiation stimulates, but via a peptide signal rather than photodamage. The pigment produced is eumelanin (brown/black), not pheomelanin.
The MC4R-mediated sexual arousal mechanism is the same pathway that PT-141 (FDA-approved Vyleesi) activates. MT-II's effect on this receptor is the basis for its persistent demand as a sexual function research peptide.
MT-II is typically used as a standalone protocol. Because it activates overlapping receptors with PT-141, those two should never be combined. The stacks below are additive without receptor overlap:
Do not combine with PT-141 — overlapping melanocortin receptor activity without additive benefit and with compounded side effects. Do not combine with PDE5 inhibitors (sildenafil, tadalafil) — priapism risk increases significantly.
Third-party COA, Finnrick-verified purity, ships within 24 hours of order. Lyophilized for transit and long-term stability.
Start Protocol Intake ← View All ProtocolsMedical Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All protocols require evaluation and prescription by a licensed physician. You should consult a qualified healthcare provider before starting any new medical protocol. Individual results vary. Cinch Bio is not a pharmacy and does not dispense medications — all prescriptions are issued by independent licensed physicians and filled by licensed 503A compounding pharmacies.